103 related articles for article (PubMed ID: 22819074)
41. [Targeting miR155 restores chemotherapy sensitivity in drug-resistant myeloma cell-line RPMI8226/DOX cells].
Xiao CR; Hong XL; Hu JS; Chen YM; Lu QY
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):55-59. PubMed ID: 28219227
[No Abstract] [Full Text] [Related]
42. Sinomenine reverses multidrug resistance in bladder cancer cells via P-glycoprotein-dependent and independent manners.
Chen Y; Zhang L; Lu X; Wu K; Zeng J; Gao Y; Shi Q; Wang X; Chang LS; He D
Pharmazie; 2014 Jan; 69(1):48-54. PubMed ID: 24601223
[TBL] [Abstract][Full Text] [Related]
43. Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma.
Ria R; Todoerti K; Berardi S; Coluccia AM; De Luisi A; Mattioli M; Ronchetti D; Morabito F; Guarini A; Petrucci MT; Dammacco F; Ribatti D; Neri A; Vacca A
Clin Cancer Res; 2009 Sep; 15(17):5369-78. PubMed ID: 19690192
[TBL] [Abstract][Full Text] [Related]
44. Collateral sensitivity to cold stress and differential BCL-2 family expression in new daunomycin-resistant lymphoblastoid cell lines.
Cerezo D; Cánovas M; García-Peñarrubia P; Martín-Orozco E
Exp Cell Res; 2015 Feb; 331(1):11-20. PubMed ID: 25498972
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of an anti-CD138 immunotoxin and doxorubicin on drug-resistant and drug-sensitive myeloma cells.
Post J; Vooijs WC; Bast BJ; De Gast GC
Int J Cancer; 1999 Nov; 83(4):571-6. PubMed ID: 10508496
[TBL] [Abstract][Full Text] [Related]
46. HMGB1 enhances chemotherapy resistance in multiple myeloma cells by activating the nuclear factor-κB pathway.
Ning J; Yang R; Wang H; Cui L
Exp Ther Med; 2021 Jul; 22(1):705. PubMed ID: 34007314
[TBL] [Abstract][Full Text] [Related]
47. Removal notice to “Translational profiling of multiple myeloma cell lines RPMI8226 and 8226/R5 to discover novel markers of disease and drug resistance” [Toxicology 290 (2011) 116].
Toxicology; 2012 Dec; 302(2-3):319. PubMed ID: 23330156
[No Abstract] [Full Text] [Related]
48. Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells.
Tsubaki M; Takeda T; Ogawa N; Sakamoto K; Shimaoka H; Fujita A; Itoh T; Imano M; Ishizaka T; Satou T; Nishida S
Leuk Res; 2015 Apr; 39(4):445-52. PubMed ID: 25726084
[TBL] [Abstract][Full Text] [Related]
49. By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells.
Tsubaki M; Komai M; Itoh T; Imano M; Sakamoto K; Shimaoka H; Takeda T; Ogawa N; Mashimo K; Fujiwara D; Mukai J; Sakaguchi K; Satou T; Nishida S
Leuk Res; 2014 Jan; 38(1):121-30. PubMed ID: 24239173
[TBL] [Abstract][Full Text] [Related]
50. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
51. Epidermal Growth Factor Receptor Inhibitor Mobocertinib Resensitizes Multidrug-Resistant Cancer Cells by Attenuating the Human ATP-Binding Cassette Subfamily B Member 1 and Subfamily G Member 2.
Li YC; Hsiao SH; Murakami M; Huang YH; Chang YT; Hung TH; Wu YS; Ambudkar SV; Wu CP
ACS Pharmacol Transl Sci; 2024 Jan; 7(1):161-175. PubMed ID: 38230272
[TBL] [Abstract][Full Text] [Related]
52. Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells.
Wu CP; Li YC; Murakami M; Hsiao SH; Lee YC; Huang YH; Chang YT; Hung TH; Wu YS; Ambudkar SV
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762275
[TBL] [Abstract][Full Text] [Related]
53. Molecular and immunological mechanisms of clonal evolution in multiple myeloma.
Forster S; Radpour R; Ochsenbein AF
Front Immunol; 2023; 14():1243997. PubMed ID: 37744361
[TBL] [Abstract][Full Text] [Related]
54. Long Noncoding RNAs in Taxane Resistance of Breast Cancer.
Chen H; Zhang M; Deng Y
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569629
[TBL] [Abstract][Full Text] [Related]
55. Bim downregulation by activation of NF-κB p65, Akt, and ERK1/2 is associated with adriamycin and dexamethasone resistance in multiple myeloma cells.
Tsubaki M; Takeda T; Matsuda T; Kishimoto K; Tanaka R; Tsurushima K; Ishizaka T; Nishida S
Clin Exp Med; 2023 Sep; 23(5):1597-1607. PubMed ID: 36451049
[TBL] [Abstract][Full Text] [Related]
56. Hydroxygenkwanin Improves the Efficacy of Cytotoxic Drugs in ABCG2-Overexpressing Multidrug-Resistant Cancer Cells.
Li YQ; Murakami M; Huang YH; Hung TH; Wang SP; Wu YS; Ambudkar SV; Wu CP
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361555
[TBL] [Abstract][Full Text] [Related]
57. The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.
Wu CP; Murakami M; Wu YS; Lin CL; Li YQ; Huang YH; Hung TH; Ambudkar SV
Biomed Pharmacother; 2022 May; 149():112922. PubMed ID: 36068781
[TBL] [Abstract][Full Text] [Related]
58. P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhiitor Ensartinib in Cancer Cells.
Wu CP; Hung CY; Murakami M; Wu YS; Lin CL; Huang YH; Hung TH; Yu JS; Ambudkar SV
Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565470
[TBL] [Abstract][Full Text] [Related]
59. The Establishment of Quantitatively Regulating Expression Cassette with sgRNA Targeting
Deng C; Hu F; Zhao Z; Zhou Y; Liu Y; Zhang T; Li S; Zheng W; Zhang W; Wang T; Ma X
Front Cell Dev Biol; 2021; 9():797005. PubMed ID: 35047507
[TBL] [Abstract][Full Text] [Related]
60. Branebrutinib (BMS-986195), a Bruton's Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents.
Wu CP; Murakami M; Wu YS; Chi YC; Hsiao SH; Huang YH; Hung TH; Ambudkar SV
Front Cell Dev Biol; 2021; 9():699571. PubMed ID: 34350184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
